Death receptor 5

Death receptor 5 (DR5), also known as TRAIL receptor 2 (TRAILR2) and tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis.

TNFRSF10B
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1D0G, 1D4V, 1DU3, 1ZA3, 2H9G, 4I9X, 4N90, 4OD2, 3X3F
Identifiers
Aliases	TNFRSF10B, CD262, DR5, KILLER, KILLER/DR5, TRAIL-R2, TRAILR2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9, tumor necrosis factor receptor superfamily member 10b, TNF receptor superfamily member 10b
External IDs	OMIM: 603612; MGI: 1341090; HomoloGene: 117702; GeneCards: TNFRSF10B; OMA:TNFRSF10B - orthologs
Gene location (Human) Chr. Chromosome 8 (human)[1] Band 8p21.3 Start 23,020,133 bp[1] End 23,069,031 bp[1]
Gene location (Mouse) Chr. Chromosome 14 (mouse)[2] Band 14|14 D2 Start 70,004,921 bp[2] End 70,021,860 bp[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in cartilage tissue mucosa of urinary bladder blood vena cava stromal cell of endometrium gallbladder germinal epithelium pericardium visceral pleura tibia Top expressed in urethra female urethra male urethra genital tubercle morula endothelial cell of lymphatic vessel tail of embryo lens embryo embryo More reference expression data BioGPS More reference expression data
Gene ontology Molecular function TRAIL binding protein binding tumor necrosis factor-activated receptor activity signaling receptor activity Cellular component membrane plasma membrane integral component of plasma membrane cell surface intracellular anatomical structure integral component of membrane Biological process activation of NF-kappaB-inducing kinase activity response to endoplasmic reticulum stress multicellular organism development cell surface receptor signaling pathway response to lipopolysaccharide intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress cellular response to mechanical stimulus regulation of cell population proliferation immune response positive regulation of I-kappaB kinase/NF-kappaB signaling regulation of extrinsic apoptotic signaling pathway via death domain receptors inflammatory response activation of cysteine-type endopeptidase activity involved in apoptotic process signal transduction tumor necrosis factor-mediated signaling pathway apoptotic process negative regulation of extrinsic apoptotic signaling pathway via death domain receptors leukocyte migration extrinsic apoptotic signaling pathway via death domain receptors regulation of apoptotic process negative regulation of cysteine-type endopeptidase activity involved in apoptotic process TRAIL-activated apoptotic signaling pathway positive regulation of apoptotic process Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 8795 21933 Ensembl ENSG00000120889 ENSMUSG00000022074 UniProt O14763 Q9QZM4 RefSeq (mRNA) NM_003842 NM_147187 NM_020275 RefSeq (protein) NP_003833 NP_671716 NP_064671 Location (UCSC) Chr 8: 23.02 – 23.07 Mb Chr 14: 70 – 70.02 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Function

The protein encoded by this gene is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces apoptosis signal. Mice have a homologous gene, tnfrsf10b, that has been essential in the elucidation of the function of this gene in humans. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.^[5]

Interactions

DR5 has been shown to interact with:

• Caspase 8,^[6][7]
• Caspase 10,^[6][7]
• FADD,^[6][8] and
• TRAIL.^[9][10][11]

Cancer therapy

Monoclonal antibodies targeting DR5 have been developed and are currently under clinical trials for patients suffer from a variety of cancer types, see Tigatuzumab (CS-1008).

Luminescent iridium complex-peptide hybrids, serving as TRAIL mimics, have been designed, which target the death receptors DR4 and DR5 on cancer cells and induce their apoptosis.^[12]

See also

• Cluster of differentiation
• Tumor necrosis factor receptor
• Tigatuzumab